International Journal of Molecular Medical Science, 2024, Vol.14, No.3, 167-176 http://medscipublisher.com/index.php/ijmms 176 Lukomska B., Stanaszek L., Zuba-Surma E., Legosz P., Sarzyńska S., and Drela K., 2019, Challenges and controversies in human mesenchymal stem cell therapy, Stem Cells International, 2019: 9628536. https://doi.org/10.1155/2019/9628536 PMid:31093291 PMCid:PMC6481040 Ouryazdanpanah N., Dabiri S., Derakhshani A., Vahidi R., and Farsinejad A., 2018, Peripheral blood-derived mesenchymal stem cells: growth factor-free isolation, molecular characterization and differentiation, Iranian Journal of Pathology, 13: 461-466. Pallua S., Giesinger J., Oberguggenberger A., Kemmler G., Nachbaur D., Clausen J., Kopp M., Sperner-Unterweger B., and Holzner B., 2010, Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation, Bone Marrow Transplantation, 45: 1534-1539. https://doi.org/10.1038/bmt.2010.5 PMid:20228854 Qi K., Li N., Zhang Z., and Melino G., 2017, Tissue regeneration: The crosstalk between mesenchymal stem cells and immune response, Cellular immunology, 326: 86-93. https://doi.org/10.1016/j.cellimm.2017.11.010 PMid:29221689 Resnick I., Barkats C., Shapira M., Stepensky P., Bloom A., Shimoni A., Mankuta D., Varda‐Bloom N., Rheingold L., Yeshurun M., Bielorai B., Toren A., Zuckerman T., Nagler A., and Or R., 2013, Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC), American journal of blood research, 3(3): 225-238. Saliba R., Lima M., Giralt S., Andersson B., Khouri I., Hosing C., Ghosh S., Neumann J., Hsu Y., Jésus J., Qazilbash M., Champlin R., and Couriel D., 2007, Hyperacute GVHD: risk factors, outcomes, and clinical implications, Blood, 109(7): 2751-2758. https://doi.org/10.1182/blood-2006-07-034348 PMid:17138825 Toubai T., Sun Y., and Reddy P., 2008, GVHD pathophysiology: is acute different from chronic? Best practice & research. Clinical haematology, 21(2): 101-117. https://doi.org/10.1016/j.beha.2008.02.005 PMid:18503979 Weng J., Weng J., Du X., Du X., Geng S., Geng S., Peng Y., Wang Z., Lu Z., Lu Z., Wu S., Wu S., Luo C., Luo C., Guo R., Guo R., Ling W., Ling W., Deng C., Deng C., Liao P., Liao P., and Xiang A., 2010, Mesenchymal stem cell as salvage treatment for refractory chronic GVHD, Bone Marrow Transplantation, 45: 1732-1740. https://doi.org/10.1038/bmt.2010.195 PMid:20818445 PMCid:PMC3035976 Wu X., Zhuang H., Zhao Y., Yu X., Dai T., and Gao R., 2020, Chinese medicine treatment on graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, Chinese Journal of Integrative Medicine, 26: 324-329. https://doi.org/10.1007/s11655-020-3252-y PMid:32350801 Xiang B., Chen L., Wang X., and Xiang C. 2017, Mesenchymal stem cells as therapeutic agents and in gene delivery for the treatment of glioma, Journal of Zhejiang University-SCIENCE B, 18: 737-746. https://doi.org/10.1631/jzus.B1600337 PMCid:PMC5611545 Yao H., Wang X., Huang R., Fu H., Lin R., Feng Y., Deng X., Chen T., Zhu L., Liu J., Liu Y., Zhao L., Wang L., Zhang C., Kong P., Gao L., Gao L., Liu Q., Zhang X., and Zhang X., 2023, A prospective, multi-center, randomized, controlled clinical trial to explore the role of mesenchymal stem cells in preventing graft versus host disease, Blood, 42(1): 3556. https://doi.org/10.1182/blood-2023-189104 Zhang D.S., and Chen Q., 2012., The Latest Application Progress of Human Umbilical Cord-Derived Mesenchymal Stem Cells (hUC-MSCs) in Neurological Diseases, nternational Journal of Psychiatry and Neurology, 1(3): 17-21. https://doi.org/10.12677/IJPN.2012.13005
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==